ACTRN12608000449336已完成2 期
A Randomised Phase II/III Trial to evaluate the efficacy and safety of Weekly Cisplatin Chemoradiotherapy +/- low-dose celecoxib for locoregional nasopharyngeal carcinoma
试验速览
- 阶段
- 2 期
- 状态
- 已完成
- 入组人数
- 50
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
- 分配方式
- Randomised controlled trial
- 主要目的
- Treatment
- 盲法
- Blinded (masking used)
入排标准
- 年龄范围
- 15 Years 至 80 Years（—）
- 性别
- All
入选标准
- •1. Pathologically proven locoregional nasopharyngeal carcinoma.
- •2. No prior therapy
- •3. No clinical or imaging evidence of distant metastasis at the time of study enrollment
- •4. Karnofsky performance status = 70
- •5. Written informed consent
- •6. Normal or acceptable liver, kidney and bone marrow function
排除标准
- •1. Prior therapy
- •2. Clinical or imaging evidence of distant metastasis
- •3. Patients with a known contraindication (e.g. gastric ulcer) or allergy to COX-2 inhibitors
- •4. Patients with severe heart, cardiovascular, liver, renal, inflammatory intestinal or blood coagulation disorders,
研究者
相似试验
进行中（未招募）
不适用
A Phase II, Open, Randomised Study to Assess the Efficacy and Safety of AZD6244 vs capecitabine (Xeloda) in Patients with Colorectal Cancer who have Failed One Or Two Prior Chemotherapeutic Regimens.metastatic colorectal cancerEUCTR2006-001457-10-HUAstraZeneca AB64
进行中（未招募）
1 期
A Phase II, Open, Randomised Study to Assess the Efficacy and Safety of AZD6244 vs capecitabine (Xeloda) in Patients with Colorectal Cancer who have Failed One Or Two Prior Chemotherapeutic Regimens.EUCTR2006-001457-10-SKAstraZeneca AB64
进行中（未招募）
不适用
A Phase II, Open, Randomised Study to Assess the Efficacy and Safety of AZD6244 vs. capecitabine (Xeloda) in Patients with Advanced or Metastatic Pancreatic Cancer, who have Failed First Line gemcitabine Therapy (Gemzar)Advanced or Metastatic Pancreatic CancerMedDRA version: 8.1Level: LLTClassification code 10033605Term: Pancreatic cancer metastaticEUCTR2006-005746-36-HUAstraZeneca AB64
进行中（未招募）
不适用
A Phase II, Open, Randomised Study to Assess the Efficacy and Safety of AZD6244 vs capecitabine (Xeloda™ ) in Patients with Colorectal Cancer who have Failed Two Prior Chemotherapeutic Regimens.EUCTR2006-001457-10-SEAstraZeneca AB64
招募中
3 期
A non-randomised Phase III study to evaluate the effectiveness of Deflazacort in boys with Duchenne muscular dystrophy in improving muscle strength and function and minimising side effects.Musculoskeletal - Other muscular and skeletal disordersDuchenne muscular dystrophyACTRN12605000077662The Children's Hospital at Westmead20